# Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression

> **NCT06774235** · PHASE3 · RECRUITING · sponsor: **University Hospital, Limoges** · enrollment: 326 (estimated)

## Conditions studied

- Sustained Immunosuppression

## Interventions

- **DRUG:** Interferon Gamma 1-b
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06774235
- **Lead sponsor:** University Hospital, Limoges
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-09
- **Primary completion:** 2028-10-09
- **Final completion:** 2028-10-09
- **Target enrollment:** 326 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06774235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06774235, "Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06774235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*